- Di sistema
- This webinar offers an integrated pathway from pathogenesis to clinical management, exploring the central role of the inflammasome and il-1¿ as key molecular drivers of fmf, supporting the use of anti-il-1¿ therapies as a disease-modifying approach. Diagnostic challenges arising from the variable clinical spectrum and overlapping inflammatory comorbidities will also be addressed, emphasizing the importance of a holistic approach. Special attention will be given to optimizing treatment in colchicine-resistant patients, focusing on il-1¿ inhibitors to control subclinical inflammation and improve clinical outcomes, supported by real-world data on canakinumab efficacy. The event aims to bridge molecular understanding with clinical evidence, providing tools for personalized therapeutic strategies and improving the quality of life of patients with fmf